Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 3 RANDOMIZED, DOUBLE BLIND PLACEBO AND NAPROXEN CONTROLLED MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE

NCT00830063 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00830063
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00830063 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 3 RANDOMIZED, DOUBLE BLIND PLACEBO AND NAPROXEN CONTROLLED MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
May 5, 2009
Completion date
August 31, 2010
Enrollment
832 (actual)
Sites
94

Conditions

As the registry lists them; a condition with its own page is linked.

arthritis, osteoarthritis